Benign prostatic hyperplasia. Current strategy and pharmacotherapeutical potential.
Dutkiewicz
S
S
Department of Urology, Ministry of Internal Affairs, Central Clinical Hospital, Warsaw, Poland.
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000728:Androgens / Q000009:adverse effects; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D000728:Androgens